Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ADMA Biologics's Debt-to-EBITDA or its related term are showing as below:
ADMA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.91 Med: -1.17 Max: 27.62
Current: 0.92
During the past 13 years, the highest Debt-to-EBITDA Ratio of ADMA Biologics was 27.62. The lowest was -3.91. And the median was -1.17.
ADMA's Debt-to-EBITDA is ranked better than 53.95% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs ADMA: 0.92
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ADMA Biologics Debt-to-EBITDA Related Terms
ADMA Biologics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, ADMA Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
ADMA Biologics (ADMA) has a Debt-to-EBITDA of 0.84 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ADMA Biologics. According to the industry distribution chart, ADMA Biologics ranks #134 out of 291 companies in the Biotechnology industry, placing it in the top 46%.
Is ADMA Biologics' Debt-to-EBITDA too high?
ADMA Biologics' current Debt-to-EBITDA is 0.84. The Biotechnology industry median Debt-to-EBITDA is 1.14. ADMA Biologics' value of 0.84 is 26.3% below this industry median. Based on the distribution chart, ADMA Biologics ranks #134 out of 291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Debt-to-EBITDA compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #134 out of 291 companies for Debt-to-EBITDA. This puts ADMA Biologics in the upper half of its industry. The industry median Debt-to-EBITDA is 1.14. ADMA Biologics' value of 0.84 is 26.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Debt-to-EBITDA of 0.84 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ADMA Biologics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Debt-to-EBITDA is 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.10, compared to a current price of $8.81 — trading 51.4% below its estimated fair value. The current Debt-to-EBITDA is 0.84 and 26.3% below the Biotechnology industry median of 1.14. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Debt-to-EBITDA is 0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.81 is trading 51.4% below its estimated GF Value™ of $18.10.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Debt-to-EBITDA: 0.84
GF Value™: $18.10 vs. price of $8.81 (51.4% below fair value)
Industry Position: 26.3% below the Biotechnology median (#134 of 291)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
